South San Francisco, Calif. — August 8, 2025 — Leads & Copy — Tenaya Therapeutics, Inc. (NASDAQ: TNYA) announced that CEO Faraz Ali will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 11:30 am ET.
The live webcast of the fireside chat will be accessible on the Investors section of Tenaya’s website, with an archived replay available for about 30 days following the live event.
Tenaya Therapeutics is focused on discovering, developing, and delivering therapies for heart disease, with a pipeline including clinical-stage candidates TN-201 and TN-401, and a clinical-stage small molecule HDAC6 inhibitor, TN-301.
Tenaya Contacts:
Michelle Corral, VP, Corporate Communications and Investor Relations, IR@tenayathera.com
Anne-Marie Fields, Precision AQ, annemarie.fields@precisionaq.com
Source: Tenaya Therapeutics
